{
  "pmcid": "PMC12679860",
  "source": "PMC",
  "download_date": "2025-12-09T16:37:18.414565",
  "metadata": {
    "journal_title": "Clinical Ophthalmology (Auckland, N.Z.)",
    "journal_nlm_ta": "Clin Ophthalmol",
    "journal_iso_abbrev": "Clin Ophthalmol",
    "journal": "Clinical Ophthalmology (Auckland, N.Z.)",
    "pmcid": "PMC12679860",
    "pmid": "41357313",
    "doi": "10.2147/OPTH.S557133",
    "title": "SCOPING: A Multidisciplinary Treatment Protocol for Neovascular Glaucoma with Completely Open or Partially Open Angles",
    "year": "2025",
    "month": "12",
    "day": "01",
    "pub_date": {
      "year": "2025",
      "month": "12",
      "day": "01"
    },
    "authors": [
      "Mokhashi Nikita",
      "Kanter Jacob",
      "Komati Rahul",
      "Mackin Anna",
      "Dao David",
      "Amin Pathik",
      "Skondra Dimitra",
      "Qiu Mary"
    ],
    "abstract": "Introduction A standardized multidisciplinary treatment protocol for NVG was developed in 2020 at the University of Chicago and has been termed Salvaging the Conventional Outflow Pathway in Neovascular Glaucoma (SCOPING). We describe 9 eyes with anterior segment neovascularization and at least partially open angles that underwent the SCOPING protocol to suppress the underlying neovascular drive, control intraocular pressure, and medically or surgically salvage the angle whenever possible. Methods Nine eyes from 8 patients with first-time anterior segment neovascularization, at least partially open angles, and normal or elevated IOP were treated with 6 serial monthly intravitreal bevacizumab injections interspersed with pan-retinal photocoagulation. Results Five eyes with completely open angles without any peripheral anterior synechiae and each achieved and/or maintained physiologic IOP without requiring surgery. The other 4 eyes presented with partially open angles. Three out of these 4 eyes required subsequent IOP-lowering surgery. None of the 9 eyes developed recurrence of anterior segment neovascularization during the treatment protocol. Discussion This protocol may be utilized to salvage the conventional outflow pathway for patients with partially or completely open angles. The etiology and diagnosis of neovascular glaucoma have been established. Current treatment strategies include reduction of neovascular drive including panretinal photocoagulation, intravitreal injections, intraocular pressure lowering medications, and filtration surgery. However, a protocol has not been developed to treat neovascular glaucoma (NVG). Our SCOPING protocol may be helpful for glaucoma specialists in treating patients with neovascular glaucoma.",
    "keywords": [
      "neovascular glaucoma",
      "micro invasive glaucoma surgeries",
      "anti-vascular endothelial growth factor",
      "pan-retinal photocoagulation"
    ]
  },
  "xml": "<?xml version=\"1.0\"  ?><!DOCTYPE pmc-articleset PUBLIC \"-//NLM//DTD ARTICLE SET 2.0//EN\" \"https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd\"><pmc-articleset><article xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:ali=\"http://www.niso.org/schemas/ali/1.0/\" xml:lang=\"en\" article-type=\"research-article\" dtd-version=\"1.4\"><processing-meta base-tagset=\"archiving\" mathml-version=\"3.0\" table-model=\"xhtml\" tagset-family=\"jats\"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type=\"nlm-ta\">Clin Ophthalmol</journal-id><journal-id journal-id-type=\"iso-abbrev\">Clin Ophthalmol</journal-id><journal-id journal-id-type=\"pmc-domain-id\">909</journal-id><journal-id journal-id-type=\"pmc-domain\">clinop</journal-id><journal-id journal-id-type=\"publisher-id\">opth</journal-id><journal-title-group><journal-title>Clinical Ophthalmology (Auckland, N.Z.)</journal-title></journal-title-group><issn pub-type=\"ppub\">1177-5467</issn><issn pub-type=\"epub\">1177-5483</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type=\"pmcid\">PMC12679860</article-id><article-id pub-id-type=\"pmcid-ver\">PMC12679860.1</article-id><article-id pub-id-type=\"pmcaid\">12679860</article-id><article-id pub-id-type=\"pmcaiid\">12679860</article-id><article-id pub-id-type=\"pmid\">41357313</article-id><article-id pub-id-type=\"doi\">10.2147/OPTH.S557133</article-id><article-id pub-id-type=\"publisher-id\">557133</article-id><article-version article-version-type=\"pmc-version\">1</article-version><article-categories><subj-group subj-group-type=\"heading\"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>SCOPING: A Multidisciplinary Treatment Protocol for Neovascular Glaucoma with Completely Open or Partially Open Angles</article-title><alt-title alt-title-type=\"running-authors\">Mokhashi et al</alt-title><alt-title alt-title-type=\"running-title\">Mokhashi et al</alt-title></title-group><contrib-group><contrib contrib-type=\"author\"><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">http://orcid.org/0000-0001-9510-3747</contrib-id><name name-style=\"western\"><surname>Mokhashi</surname><given-names initials=\"N\">Nikita</given-names></name><xref rid=\"aff0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Kanter</surname><given-names initials=\"J\">Jacob</given-names></name><xref rid=\"aff0002\" ref-type=\"aff\">\n<sup>2</sup>\n</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Komati</surname><given-names initials=\"R\">Rahul</given-names></name><xref rid=\"aff0003\" ref-type=\"aff\">\n<sup>3</sup>\n</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Mackin</surname><given-names initials=\"A\">Anna</given-names></name><xref rid=\"aff0004\" ref-type=\"aff\">\n<sup>4</sup>\n</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Dao</surname><given-names initials=\"D\">David</given-names></name><xref rid=\"aff0005\" ref-type=\"aff\">\n<sup>5</sup>\n</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Amin</surname><given-names initials=\"P\">Pathik</given-names></name><xref rid=\"aff0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Skondra</surname><given-names initials=\"D\">Dimitra</given-names></name><xref rid=\"aff0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref></contrib><contrib contrib-type=\"author\"><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">http://orcid.org/0000-0002-0062-7386</contrib-id><name name-style=\"western\"><surname>Qiu</surname><given-names initials=\"M\">Mary</given-names></name><xref rid=\"aff0006\" ref-type=\"aff\">\n<sup>6</sup>\n</xref><xref rid=\"an0001\" ref-type=\"corresp\"/></contrib><aff id=\"aff0001\"><label>1</label><institution>Department of Ophthalmology and Visual Science, University of Chicago</institution>, <addr-line>Chicago</addr-line>, <addr-line>IL</addr-line>, <country>USA</country></aff><aff id=\"aff0002\"><label>2</label><institution>Wilmer Eye Institute, Johns Hopkins University</institution>, <addr-line>Baltimore</addr-line>, <addr-line>MD</addr-line>, <country>USA</country></aff><aff id=\"aff0003\"><label>3</label><institution>Georgia Retina</institution>, <addr-line>Macon</addr-line>, <addr-line>GA</addr-line>, <country>USA</country></aff><aff id=\"aff0004\"><label>4</label><institution>Vistar Eye Center</institution>, <addr-line>Roanoke</addr-line>, <addr-line>VA</addr-line>, <country>USA</country></aff><aff id=\"aff0005\"><label>5</label><institution>Elman Retina Group</institution>, <addr-line>Rosedale</addr-line>, <addr-line>MD</addr-line>, <country>USA</country></aff><aff id=\"aff0006\"><label>6</label><institution>Cole Eye Institute, Cleveland Clinic</institution>, <addr-line>Cleveland</addr-line>, <addr-line>OH</addr-line>, <country>USA</country></aff></contrib-group><author-notes><corresp id=\"an0001\">Correspondence: Mary Qiu, <institution>Cole Eye Institute, Cleveland Clinic</institution>, <addr-line>2022 E 105<sup>th</sup> St</addr-line>, <addr-line>Cleveland</addr-line>, <addr-line>OH</addr-line>, <addr-line>44106</addr-line>, <country>USA</country>, Email mary.qiu@gmail.com</corresp></author-notes><pub-date pub-type=\"epub\"><day>01</day><month>12</month><year>2025</year></pub-date><pub-date pub-type=\"collection\"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type=\"pmc-issue-id\">478874</issue-id><fpage>4373</fpage><lpage>4379</lpage><history><date date-type=\"received\"><day>30</day><month>7</month><year>2025</year></date><date date-type=\"accepted\"><day>11</day><month>11</month><year>2025</year></date></history><pub-history><event event-type=\"pmc-release\"><date><day>01</day><month>12</month><year>2025</year></date></event><event event-type=\"pmc-live\"><date><day>06</day><month>12</month><year>2025</year></date></event><event event-type=\"pmc-last-change\"><date iso-8601-date=\"2025-12-08 15:25:12.403\"><day>08</day><month>12</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Mokhashi et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Mokhashi et al.</copyright-holder><license><ali:license_ref specific-use=\"textmining\" content-type=\"ccbynclicense\">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://www.dovepress.com/terms.php\">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v4.0) License (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://creativecommons.org/licenses/by-nc/4.0/\">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://www.dovepress.com/terms.php\">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"pmc-pdf\" xlink:href=\"opth-19-4373.pdf\"/><abstract><sec sec-type=\"intro\"><title>Introduction</title><p>A standardized multidisciplinary treatment protocol for NVG was developed in 2020 at the University of Chicago and has been termed Salvaging the Conventional Outflow Pathway in Neovascular Glaucoma (SCOPING). We describe 9 eyes with anterior segment neovascularization and at least partially open angles that underwent the SCOPING protocol to suppress the underlying neovascular drive, control intraocular pressure, and medically or surgically salvage the angle whenever possible.</p></sec><sec><title>Methods</title><p>Nine eyes from 8 patients with first-time anterior segment neovascularization, at least partially open angles, and normal or elevated IOP were treated with 6 serial monthly intravitreal bevacizumab injections interspersed with pan-retinal photocoagulation.</p></sec><sec><title>Results</title><p>Five eyes with completely open angles without any peripheral anterior synechiae and each achieved and/or maintained physiologic IOP without requiring surgery. The other 4 eyes presented with partially open angles. Three out of these 4 eyes required subsequent IOP-lowering surgery. None of the 9 eyes developed recurrence of anterior segment neovascularization during the treatment protocol.</p></sec><sec><title>Discussion</title><p>This protocol may be utilized to salvage the conventional outflow pathway for patients with partially or completely open angles. The etiology and diagnosis of neovascular glaucoma have been established. Current treatment strategies include reduction of neovascular drive including panretinal photocoagulation, intravitreal injections, intraocular pressure lowering medications, and filtration surgery. However, a protocol has not been developed to treat neovascular glaucoma (NVG). Our SCOPING protocol may be helpful for glaucoma specialists in treating patients with neovascular glaucoma.</p></sec></abstract><kwd-group kwd-group-type=\"author\"><title>Keywords</title><kwd>neovascular glaucoma</kwd><kwd>micro invasive glaucoma surgeries</kwd><kwd>anti-vascular endothelial growth factor</kwd><kwd>pan-retinal photocoagulation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>funding or grant support</institution></institution-wrap></funding-source></award-group><funding-statement>No funding or grant support was used.</funding-statement></funding-group><counts><fig-count count=\"0\"/><table-count count=\"1\"/><ref-count count=\"17\"/><page-count count=\"7\"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type=\"intro\" id=\"s0001\"><title>Introduction</title><p>Neovascular glaucoma (NVG) is a secondary glaucoma that occurs when retinal ischemia leads to the proliferation of fibrovascular tissue anteriorly, leading to neovascularization of the iris (NVI) and/or angle (NVA) with a subsequent increase in intraocular pressure (IOP).<xref rid=\"cit0001\" ref-type=\"bibr\">1</xref> The management of NVG centers around reducing the vascular endothelial growth factor (VEGF) load and controlling IOP. The two approaches to reduce the VEGF load are intravitreal anti-VEGF therapy such as bevacizumab (IVB) and panretinal photocoagulation (PRP). IVB leads to rapid regression of NVA and NVI which can also contribute to IOP-lowering if the angle is at least partially open and functional.<xref rid=\"cit0002\" ref-type=\"bibr\">2</xref> While anti-VEGF works immediately, PRP is the gold standard long term solution as it decreases the underlying neovascular drive by inducing tissue coagulation thereby decreasing the production of angiogenic factors by peripheral ischemic retina.<xref rid=\"cit0003\" ref-type=\"bibr\">3</xref></p><p>If the patient presents with NVI or NVA without synechial closure, regression of the anterior neovascularization through anti-VEGF and PRP may be sufficient to achieve physiologic IOP without the need for any glaucoma intervention.<xref rid=\"cit0004\" ref-type=\"bibr\">4</xref> However, eyes with NVG that have already developed partial or total synechial angle closure often require interventions such as tube shunt implantation or cyclophotocoagulation (CPC) to achieve long-term IOP control.<xref rid=\"cit0005\" ref-type=\"bibr\">5</xref>,<xref rid=\"cit0006\" ref-type=\"bibr\">6</xref> As a whole, long-term NVG outcomes leave much to be desired,<xref rid=\"cit0007\" ref-type=\"bibr\">7</xref> and there are many barriers to achieving optimal outcomes in NVG.<xref rid=\"cit0008\" ref-type=\"bibr\">8</xref> For this reason, a standardized multidisciplinary treatment protocol for NVG was developed in 2020 in collaboration between a glaucoma (MQ) and retina (DS) specialist at the University of Chicago and has been termed Salvaging the Conventional Outflow Pathway in Neovascular Glaucoma (SCOPING). For eyes with anterior segment neovascularization (NVI or NVA) and at least partially open angles, regardless of presenting IOP or presumed visual potential (as long as not already NLP at presentation), we offer an aggressive anti-neovascular treatment protocol in an attempt to medically salvage the conventional outflow pathway and reduce the need for subsequent IOP-lowering surgeries. If IOP becomes uncontrolled on maximum medical therapy, angle-based surgeries may be offered to qualifying patients with the goal of salvaging the conventional outflow pathway whenever possible and delaying or potentially avoiding a tube shunt or CPC.</p></sec><sec id=\"s0002\"><title>Materials and Methods</title><p>Approval was obtained from the University of Chicago Institutional Review Board (IRB) to perform a retrospective chart review to describe treatment outcomes. Patient consent to review medical records was not required per the University of Chicago IRB given the deidentified nature of the data collected. This work adhered to the 1964 Helsinki declaration and its later amendments. Patients with first-time anterior segment neovascularization (NVI or NVA) and at least partially open angles (defined as no more than 270&#176; of synechial closure) and normal or elevated IOP<xref rid=\"cit0009\" ref-type=\"bibr\">9</xref> were treated with 6 planned serial monthly IVB injections interspersed with sessions of PRP at the discretion of the retina service with the goal of providing anti-neovascular coverage with the planned monthly injections while sufficient PRP is administered. Given the practice patterns of the retina service, we collaboratively decided to standardize the treatment protocol to 6 scheduled monthly injections, to provide up to 6 months of time for the PRP to be completed. However, depending on the retina specialists&#8217; practice pattern, patients may require greater or fewer than 6 monthly injections to provide an adequate umbrella of anti-neovascular protection while sufficient PRP is completed. Qualifying patients were stratified into 3 stages of disease: patients with NVI or NVA, normal IOP, and absence of PAS; patients with NVI or NVA, elevated IOP, and absence of PAS; and patients with NVI or NVA, elevated IOP, and presence of PAS with partial synechial closure (&lt;75% closure). IVB injections were encouraged to be spaced by 28 days to maintain continuous anti-neovascular protection while the eye undergoes multiple sessions of PRP which has a slower onset of action.<xref rid=\"cit0003\" ref-type=\"bibr\">3</xref>,<xref rid=\"cit0010\" ref-type=\"bibr\">10</xref>,<xref rid=\"cit0011\" ref-type=\"bibr\">11</xref> If the IOP became elevated despite maximum medical IOP-lowering therapy, and there was no active anterior segment neovascularization, then angle surgery such as gonioscopy assisted transluminal trabeculotomy (GATT) was offered in an attempt to surgically salvage the conventional outflow pathway. Contraindications for GATT included monocular status and inability to hold antiplatelet/anticoagulation. Patients who were considered candidates for GATT first could alternatively elect primary aqueous shunt or CPC instead, depending on the clinical circumstances. Herein, we report pilot results from 9 consecutive NVG eyes that completed the SCOPING protocol, defined as completing 6 scheduled monthly anti-VEGF injections, with as many interspersed PRP sessions as was deemed necessary by the retina service.</p></sec><sec id=\"s0003\"><title>Results</title><p>In total, 9 eyes from 8 patients qualified for and completed the SCOPING protocol. Presenting clinical characteristics and outcomes are shown in <xref rid=\"t0001\" ref-type=\"table\">Table 1</xref>. Humphrey visual field and OCT testing can be confounded in the setting of NVG due to corneal and retinal findings leading to misinterpretation, thus they were not necessarily performed at baseline in these NVG patients.<xref rid=\"cit0012\" ref-type=\"bibr\">12</xref>,<xref rid=\"cit0013\" ref-type=\"bibr\">13</xref> The 2 eyes with anterior segment neovascularization and normal IOP were diagnosed despite being asymptomatic because their fellow eye presented symptomatically with NVG and total synechial angle closure.<table-wrap position=\"float\" id=\"t0001\" orientation=\"landscape\"><label>Table 1</label><caption><p>Demographic Characteristics and Clinical Features of Eyes Presenting with NVI/NVA and Completely or Partially Open Angles Undergoing SCOPING Protocol</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th rowspan=\"1\" colspan=\"1\">Eye</th><th rowspan=\"1\" colspan=\"1\">Age at Presentation</th><th rowspan=\"1\" colspan=\"1\">Gender (M/F)</th><th rowspan=\"1\" colspan=\"1\">Race</th><th rowspan=\"1\" colspan=\"1\">Etiology</th><th rowspan=\"1\" colspan=\"1\">PRP Prior to Presentation of NVG</th><th rowspan=\"1\" colspan=\"1\">Aspirin/AC Use</th><th rowspan=\"1\" colspan=\"1\">Initial VA</th><th rowspan=\"1\" colspan=\"1\">Initial IOP (mmHg)</th><th rowspan=\"1\" colspan=\"1\">Iris/Angle Exam</th><th rowspan=\"1\" colspan=\"1\">Duration Between 6 IVBs (Days)</th><th rowspan=\"1\" colspan=\"1\"># PRP Session (# of Spots) Within Protocol Period</th><th rowspan=\"1\" colspan=\"1\">VA 1 Month After IVB #6</th><th rowspan=\"1\" colspan=\"1\">IOP 1 Month After IVB #6</th><th rowspan=\"1\" colspan=\"1\">Recurrent NV During Study Period?</th><th rowspan=\"1\" colspan=\"1\">Recurrent NV After Study Period?</th><th rowspan=\"1\" colspan=\"1\">IOP-Lowering Surgery at Any Point</th><th rowspan=\"1\" colspan=\"1\">Subsequent Anti-VEGF Therapy After Protocol Period</th><th rowspan=\"1\" colspan=\"1\"># Days Since Protocol Completion to Last Visit</th><th rowspan=\"1\" colspan=\"1\">VA at Last Visit</th><th rowspan=\"1\" colspan=\"1\">IOP at Last Visit</th></tr></thead><tbody><tr><td colspan=\"21\" align=\"center\" rowspan=\"1\"><bold>Anterior Segment Neovascularization with Normal IOP</bold></td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #1</bold></td><td rowspan=\"1\" colspan=\"1\">60s</td><td rowspan=\"1\" colspan=\"1\">F</td><td rowspan=\"1\" colspan=\"1\">Black</td><td rowspan=\"1\" colspan=\"1\">PDR</td><td rowspan=\"1\" colspan=\"1\">Yes</td><td rowspan=\"1\" colspan=\"1\">AC</td><td rowspan=\"1\" colspan=\"1\">20/25</td><td rowspan=\"1\" colspan=\"1\">14 on 0 meds</td><td rowspan=\"1\" colspan=\"1\"><bold>NVI</bold>, no NVA, no PAS</td><td rowspan=\"1\" colspan=\"1\">33, 37, 48, 43, 42</td><td rowspan=\"1\" colspan=\"1\">3 (1677)</td><td rowspan=\"1\" colspan=\"1\">20/20</td><td rowspan=\"1\" colspan=\"1\">9 on 0 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">Subsequent IVB &amp; PRP&#8224; and aflibercept</td><td rowspan=\"1\" colspan=\"1\">980</td><td rowspan=\"1\" colspan=\"1\">20/40</td><td rowspan=\"1\" colspan=\"1\">14 on 0 meds</td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #2*</bold></td><td rowspan=\"1\" colspan=\"1\">60s</td><td rowspan=\"1\" colspan=\"1\">M</td><td rowspan=\"1\" colspan=\"1\">Black</td><td rowspan=\"1\" colspan=\"1\">PDR</td><td rowspan=\"1\" colspan=\"1\">Yes</td><td rowspan=\"1\" colspan=\"1\">AC</td><td rowspan=\"1\" colspan=\"1\">20/50</td><td rowspan=\"1\" colspan=\"1\">15 on 0 meds</td><td rowspan=\"1\" colspan=\"1\"><bold>NVI</bold>, no NVA, no PAS</td><td rowspan=\"1\" colspan=\"1\">28, 30, 77, 33, 28</td><td rowspan=\"1\" colspan=\"1\">1 (642)</td><td rowspan=\"1\" colspan=\"1\">20/30</td><td rowspan=\"1\" colspan=\"1\">19 on 0 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">Subsequent IVB</td><td rowspan=\"1\" colspan=\"1\">539</td><td rowspan=\"1\" colspan=\"1\">20/30</td><td rowspan=\"1\" colspan=\"1\">18 on 0 meds</td></tr><tr><td colspan=\"21\" align=\"center\" rowspan=\"1\"><bold>Anterior Segment Neovascularization with Elevated IOP and an Open Angle without PAS</bold></td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #3*</bold></td><td rowspan=\"1\" colspan=\"1\">60s</td><td rowspan=\"1\" colspan=\"1\">M</td><td rowspan=\"1\" colspan=\"1\">Hispanic</td><td rowspan=\"1\" colspan=\"1\">PDR</td><td rowspan=\"1\" colspan=\"1\">Yes</td><td rowspan=\"1\" colspan=\"1\">ASA</td><td rowspan=\"1\" colspan=\"1\">20/30</td><td rowspan=\"1\" colspan=\"1\">38 on 0 meds</td><td rowspan=\"1\" colspan=\"1\"><bold>NVI, faint NVA</bold>, no PAS</td><td rowspan=\"1\" colspan=\"1\">28, 69, 42, 42, 28</td><td rowspan=\"1\" colspan=\"1\">3 (1878)</td><td rowspan=\"1\" colspan=\"1\">20/25</td><td rowspan=\"1\" colspan=\"1\">12 on 2 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">None at 56 days</td><td rowspan=\"1\" colspan=\"1\">44</td><td rowspan=\"1\" colspan=\"1\">20/25</td><td rowspan=\"1\" colspan=\"1\">12 on 2 meds</td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #4*</bold></td><td rowspan=\"1\" colspan=\"1\">60s</td><td rowspan=\"1\" colspan=\"1\">M</td><td rowspan=\"1\" colspan=\"1\">Hispanic</td><td rowspan=\"1\" colspan=\"1\">PDR</td><td rowspan=\"1\" colspan=\"1\">Yes</td><td rowspan=\"1\" colspan=\"1\">ASA</td><td rowspan=\"1\" colspan=\"1\">20/40</td><td rowspan=\"1\" colspan=\"1\">41 on 0 meds</td><td rowspan=\"1\" colspan=\"1\"><bold>NVI, faint NVA</bold>, no PAS</td><td rowspan=\"1\" colspan=\"1\">28, 63, 42, 42, 28</td><td rowspan=\"1\" colspan=\"1\">2 (1303)</td><td rowspan=\"1\" colspan=\"1\">20/30</td><td rowspan=\"1\" colspan=\"1\">10 on 2 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">Subsequent PRP</td><td rowspan=\"1\" colspan=\"1\">51</td><td rowspan=\"1\" colspan=\"1\">20/30</td><td rowspan=\"1\" colspan=\"1\">10 on 2 meds</td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #5</bold></td><td rowspan=\"1\" colspan=\"1\">60s</td><td rowspan=\"1\" colspan=\"1\">M</td><td rowspan=\"1\" colspan=\"1\">Caucasian</td><td rowspan=\"1\" colspan=\"1\">OIS</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">20/50</td><td rowspan=\"1\" colspan=\"1\">47 on 0 meds</td><td rowspan=\"1\" colspan=\"1\"><bold>NVI, faint NVA</bold>, no PAS</td><td rowspan=\"1\" colspan=\"1\">28, 35, 28, 28, 33</td><td rowspan=\"1\" colspan=\"1\">3 (1907)</td><td rowspan=\"1\" colspan=\"1\">20/20</td><td rowspan=\"1\" colspan=\"1\">19 on 0 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">Yes&#8225;</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">Subsequent IVB &amp; PRP</td><td rowspan=\"1\" colspan=\"1\">920</td><td rowspan=\"1\" colspan=\"1\">20/20</td><td rowspan=\"1\" colspan=\"1\">19 on 0 meds</td></tr><tr><td colspan=\"21\" align=\"center\" rowspan=\"1\"><bold>Anterior Segment Neovascularization with Elevated IOP and Partial Synechial Closure (&lt;75% closure)</bold></td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #6</bold></td><td rowspan=\"1\" colspan=\"1\">20s</td><td rowspan=\"1\" colspan=\"1\">M</td><td rowspan=\"1\" colspan=\"1\">Black</td><td rowspan=\"1\" colspan=\"1\">PDR</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">20/40</td><td rowspan=\"1\" colspan=\"1\">22 on 0 meds</td><td rowspan=\"1\" colspan=\"1\"><bold>NVI, frank NVA, 30% PAS</bold></td><td rowspan=\"1\" colspan=\"1\">29, 28, 28, 28, 28</td><td rowspan=\"1\" colspan=\"1\">3 (3268)</td><td rowspan=\"1\" colspan=\"1\">20/40</td><td rowspan=\"1\" colspan=\"1\">20 on 0 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">Yes**</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">Subsequent IVB &amp; PRP</td><td rowspan=\"1\" colspan=\"1\">459</td><td rowspan=\"1\" colspan=\"1\">20/40</td><td rowspan=\"1\" colspan=\"1\">17 on 2 meds</td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #7</bold></td><td rowspan=\"1\" colspan=\"1\">40s</td><td rowspan=\"1\" colspan=\"1\">M</td><td rowspan=\"1\" colspan=\"1\">Hispanic</td><td rowspan=\"1\" colspan=\"1\">PDR</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">20/100</td><td rowspan=\"1\" colspan=\"1\">31 on 4 meds</td><td rowspan=\"1\" colspan=\"1\">Regressed NVI, no NVA, <bold>50% PAS</bold></td><td rowspan=\"1\" colspan=\"1\">28, 38, 29, 23, 40</td><td rowspan=\"1\" colspan=\"1\">1 (&#167;&#167;)</td><td rowspan=\"1\" colspan=\"1\">20/50</td><td rowspan=\"1\" colspan=\"1\">13 on 3 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">Yes</td><td rowspan=\"1\" colspan=\"1\">GATT &amp; IVTA&#8224;&#8224; between IVB #1 and #2; subsequent BGI 350</td><td rowspan=\"1\" colspan=\"1\">Subsequent IVB &amp; PRP</td><td rowspan=\"1\" colspan=\"1\">241</td><td rowspan=\"1\" colspan=\"1\">20/400</td><td rowspan=\"1\" colspan=\"1\">18 on 1 med</td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #8*</bold></td><td rowspan=\"1\" colspan=\"1\">50s</td><td rowspan=\"1\" colspan=\"1\">F</td><td rowspan=\"1\" colspan=\"1\">Black</td><td rowspan=\"1\" colspan=\"1\">CRVO</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">None</td><td rowspan=\"1\" colspan=\"1\">HM</td><td rowspan=\"1\" colspan=\"1\">45 on 0 meds</td><td rowspan=\"1\" colspan=\"1\"><bold>NVI, frank NVA, 50% PAS</bold></td><td rowspan=\"1\" colspan=\"1\">35, 61, 51, 33, 44</td><td rowspan=\"1\" colspan=\"1\">2 (2386)</td><td rowspan=\"1\" colspan=\"1\">20/200</td><td rowspan=\"1\" colspan=\"1\">15 on 2 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">Yes***</td><td rowspan=\"1\" colspan=\"1\">GATT between IVB #2 and #3; subsequent CPC &amp; BGI 350</td><td rowspan=\"1\" colspan=\"1\">Subsequent IVB &amp; PRP</td><td rowspan=\"1\" colspan=\"1\">439</td><td rowspan=\"1\" colspan=\"1\">20/125</td><td rowspan=\"1\" colspan=\"1\">8 on 0 meds</td></tr><tr><td rowspan=\"1\" colspan=\"1\"><bold>Eye #9</bold></td><td rowspan=\"1\" colspan=\"1\">50s</td><td rowspan=\"1\" colspan=\"1\">F</td><td rowspan=\"1\" colspan=\"1\">Black</td><td rowspan=\"1\" colspan=\"1\">PDR</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">ASA</td><td rowspan=\"1\" colspan=\"1\">20/40</td><td rowspan=\"1\" colspan=\"1\">31 on 0 meds</td><td rowspan=\"1\" colspan=\"1\">NVI, frank NVA, 50% PAS</td><td rowspan=\"1\" colspan=\"1\">34, 23, 40, 72, 35</td><td rowspan=\"1\" colspan=\"1\">2 (1933)</td><td rowspan=\"1\" colspan=\"1\">20/30</td><td rowspan=\"1\" colspan=\"1\">18 on 0 meds</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">No</td><td rowspan=\"1\" colspan=\"1\">BGI 350 between IVB #1 and #2</td><td rowspan=\"1\" colspan=\"1\">Subsequent IVB &amp; PRP&#167;</td><td rowspan=\"1\" colspan=\"1\">776</td><td rowspan=\"1\" colspan=\"1\">20/30</td><td rowspan=\"1\" colspan=\"1\">11 on 4 meds</td></tr></tbody></table><table-wrap-foot><fn id=\"tfn0001\"><p><bold>Notes</bold>: *Four eyes from 3 patients who died after completion of the protocol; &#8224;Starting 152 days after IVB #6 for vitreous hemorrhage; &#167;&#167; # of PRP spots not documented in electronic medical record. &#8224;&#8224;80 days after IVB #6 for recurrent NVA; **158 days after IVB #6; &#8224;&#8224;intravitreal triamcinolone acetonide; ***119 days after IVB #6 for recurrent NVA; &#167;Further IVB in order to dry out CME prior to performing fill-in PRP.</p></fn><fn id=\"tfn0002\"><p><bold>Abbreviations</bold>: AC, anticoagulation; BGI350, Baerveldt 350; CPC, Cyclophotocoagulation; CRVO, Central retinal vein occlusion; F, female; GATT, Gonioscopy-assisted transluminal trabeculotomy; HM, Hand motion; IOP, Intraocular pressure; IVB, Intravitreal bevacizumab; M, male; NVA, Neovascularization of the angle; NV, Neovascularization; NVG, Neovascular Glaucoma; NVI, Neovascularization of the iris; OIS, Ocular ischemic syndrome; PAS, Peripheral anterior synechiae; PDR, Proliferative diabetic retinopathy; PRP, Panretinal photocoagulation; VA, Visual acuity; VEGF, Vascular endothelial growth factor.</p></fn></table-wrap-foot></table-wrap></p><p>There were 5 male patients, and 5 patients were African American. The median age was 60.5 years (range 25&#8211;68). The median presenting VA was 20/40 and the mean presenting IOP was 31&#160;mmHg on 0 medications. IVB was given within 1 day of diagnosis for all but 1 patient who received an injection at a referring doctor&#8217;s office 7 days prior to urgent follow up with University of Chicago. Median duration between subsequent IVBs was 35 days (range 23 to 77), median time from IVB #1 to IVB #6 was 203 days (range 152 to 224), and median number of PRP sessions during the protocol period was 2 (range 1&#8211;3). One month after IVB #6, median IOP was 15&#160;mmHg (range 9&#8211;20) on a median of 2 medications (range 0&#8211;2).</p><p>Five eyes presented with anterior segment neovascularization and a completely open angle without any peripheral anterior synechiae (PAS). Among these, 2 eyes had normal IOP and NVA while 3 eyes had elevated IOP and NVA. These 5 eyes all achieved and/or maintained physiologic IOP without IOP-lowering surgery to date. Notably, 3 of the 5 eyes underwent subsequent IVB beyond the 6-month SCOPING protocol period: one for cystoid macular edema secondary to PDR, one for vitreous hemorrhage secondary to PDR, and one for recurrent NVA and elevated IOP in the setting of ocular ischemic syndrome.<xref rid=\"cit0004\" ref-type=\"bibr\">4</xref> These 3 angles remained completely open with the resumption of serial anti-VEGF therapy.</p><p>Among the 4 eyes (eyes #6-9) with partial angle closure at the time of presentation, 1 eye (eye #6) was still partially open after completion of the SCOPING protocol and has not required any further procedures. The other 3 eyes (eye #7-9) underwent further procedures.</p><p>Eye #7 underwent a GATT between IVB #1 and #2 for elevated IOP on 4 medications. Although GATT is typically contraindicated in eyes with PAS, it can be completed<xref rid=\"cit0014\" ref-type=\"bibr\">14</xref> and was successfully performed in eye #8 with NVG and PAS.<xref rid=\"cit0015\" ref-type=\"bibr\">15</xref> After GATT, eye #7 received anti-VEGF injections with a local retina specialist but there was a lapse in retina follow-up, and this eye did not receive anti-VEGF injections for 82 days. Due to this lapse, this eye subsequently developed recurrent NVI and NVA with total synechial angle closure and elevated IOP and underwent a Baerveldt-350 in the sulcus 5 months after SCOPING protocol completion. This was likely due to incomplete PRP as this patient had only 1 session.</p><p>Similarly, eye #8 also underwent GATT 35 days after NVG presentation. Eye #8 subsequently achieved medication-free IOP control for 9 months while undergoing monthly anti-VEGF injections before subsequently becoming lost to follow-up. This eye developed recurrent disease with subsequent total synechial angle closure, requiring Baerveldt-350 in the sulcus 9 months after completing the SCOPING protocol.<xref rid=\"cit0015\" ref-type=\"bibr\">15</xref> In eyes #7 and #8 with progressive synechial closure, the anti-VEGF had ample time to take effect in regressing anterior segment neovascularization since the angle was partially open on presentation, so GATT could be performed after regression. Eye #9, despite initially being an anatomic candidate for GATT, underwent Baerveldt-350 in the sulcus 8 days after NVG presentation as the patient elected for an aqueous shunt instead.</p></sec><sec id=\"s0004\"><title>Discussion</title><p>Our results demonstrate the value of prompt and aggressive anti-VEGF treatment for anterior segment neovascularization with completely open or partially open angles. IVB leads to immediate regression of NVI and NVA which is maintained while serial injections keep neovascularization at bay. Under the coverage of monthly IVB, interspersed sessions of PRP exert a long-lasting effect beyond the completion of injections. Once sufficient PRP has been completed, serial monthly injections can be stopped. However, it is important to realize that sufficient PRP is difficult to define. The Early Treatment Diabetic Retinopathy Study (ETDRS) defined sufficient PRP as 1200 to 1600 burns which should extend to the edge of an oval area including the disc and macula, and anteriorly to or beyond the equator.<xref rid=\"cit0016\" ref-type=\"bibr\">16</xref></p><p>Of the eyes that had recurrence after completion of the study protocol (eyes #5-8), eye #7 only had 1 session of PRP which was insufficient according to this definition. The other 3 eyes (eyes #5, #6 and #8) did have greater than 1600 burns documented. It is possible that these 3 eyes also did not have sufficient PRP but it is also possible that despite maximal PRP, they had persistent neovascularization from uveal ischemia which would not be addressed by PRP.<xref rid=\"cit0016\" ref-type=\"bibr\">16</xref> Indeed, there are some choroidal vascular changes that have been documented in PDR and DME, including decreased combined thickness of the choriocapillaris and medium choroidal vessel layers.<xref rid=\"cit0017\" ref-type=\"bibr\">17</xref></p><p>Once PRP is completed, one could consider obtaining a fluorescein angiogram to assess for areas of persistent leakage, or OCT angiography to assess for choroidal ischemia. With prompt control of neovascular drive, there may be a window of opportunity to salvage the angle medically or surgically, if necessary.</p><p>Our results reflect the importance of stratifying eyes with anterior segment neovascularization by angle status as described above. For eyes that present with anterior segment neovascularization with a completely open angle, this protocol may allow them to maintain or achieve physiologic IOP without any subsequent IOP-lowering surgery. For eyes that present with partial synechial angle closure, this protocol allows rapid regression of anterior segment neovascularization and temporary improvement of IOP so that any subsequent IOP-lowering surgery can be considered only after anterior segment neovascularization has fully regressed. Microinvasive glaucoma surgeries such as GATT may be attempted to surgically salvage and/or restore the conventional outflow pathway in select eyes if the patient and team are committed to close follow-up and ongoing treatment.</p><p>Of the 4 patients who had NVI/NVA with elevated IOP and PAS with partial synechial closure, 3 required IOP-lowering surgery as described above. The patient who elected to have primary BGI 350 did not have recurrence of neovascularization (eye #9). However, the other 2 patients (eyes #7 and #8) who elected to try GATT first may have had insufficient PRP during the 6-month window of anti-VEGF to completely regress their neovascular drive. Thus, while their IOP was controlled during their monthly anti-VEGF in the protocol period, they developed recurrent NVA with subsequent progressive synechial angle closure requiring additional IOP-lowering surgery with BGI-350 in the sulcus. These 2 patients demonstrate that the angle can be salvaged as long as the neovascular drive is controlled. Crucially, sufficient PRP must be completed while patients are receiving short-term coverage with anti-VEGF in order to allow long term control once the injections are stopped. If they do not get full PRP within this period of coverage, neovascularization may recur if there is a break in regular injections.</p><p>Each of the patients in this pilot study had at least a partially open angle. In NVG eyes with total synechial closure (defined as more than 270&#176; of synechial closure) and active anterior segment neovascularization, prompt cyclophotocoagulation with anti-VEGF was recommended as the primary intervention, and we have published our outcomes for those patients separately.<xref rid=\"cit0005\" ref-type=\"bibr\">5</xref> In such patients, IOP would not be expected to improve with regression of anterior segment neovascularization as the angle is already synechially closed.<xref rid=\"cit0009\" ref-type=\"bibr\">9</xref></p><p>Our study has limitations. First it is a retrospective pilot study with small sample size. Additionally, as it is based on 9 individual patients, there is variability in compliance with treatment and follow up. However, we offer a novel and unique protocol to treat neovascular glaucoma which is valuable given the limited guidelines currently available.</p></sec><sec id=\"s0005\"><title>Conclusion</title><p>The SCOPING protocol may be utilized to salvage the conventional outflow pathway for patients with any anterior segment neovascularization regardless of IOP when the angle is completely or partially open. Further directions include comparison of outcomes in patients with neovascular glaucoma treated prior to the development of the SCOPING protocol.</p></sec></body><back><ack><title>Acknowledgments</title><p>The abstract of this paper was presented at the Women in Ophthalmology Conference in 2023 as a poster presentation with interim findings.</p></ack><sec sec-type=\"data-availability\" id=\"s0006\"><title>Data Sharing Statement</title><p>Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.</p></sec><sec id=\"s0007\"><title>Patient Consent</title><p>Consent to publish personal information and case details was obtained verbally from the patients included in this report. No individual patients are identifiable by their case description.</p></sec><sec sec-type=\"COI-statement\" id=\"s0008\"><title>Disclosure</title><p>Mary Qiu reports personal fees from Lantrek, personal fees from New World Medical, personal fees from Abbvie, personal fees from Nova, outside the submitted work. The authors report no other conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id=\"cit0001\"><label>1.</label><mixed-citation publication-type=\"book\"><string-name name-style=\"western\"><surname>Khanna</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Chang</surname><given-names>DS</given-names></string-name>. <part-title>Epidemiology of neovascular glaucoma</part-title>. In: <string-name name-style=\"western\"><surname>Qiu</surname><given-names>M</given-names></string-name> editor. <source><italic toggle=\"yes\">Neovascular Glaucoma</italic></source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2022</year>:<fpage>5</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1007/978-3-031-11720-6_2</pub-id>.</mixed-citation></ref><ref id=\"cit0002\"><label>2.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Yazdani</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Hendi</surname><given-names>K</given-names></string-name>, <string-name name-style=\"western\"><surname>Pakravan</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Mahdavi</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Yaseri</surname><given-names>M</given-names></string-name>. <article-title>Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial</article-title>. <source><italic toggle=\"yes\">J Glaucoma</italic></source>. <year>2009</year>;<volume>18</volume>(<issue>8</issue>):<fpage>632</fpage>&#8211;<lpage>637</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1097/IJG.0b013e3181997211</pub-id><pub-id pub-id-type=\"pmid\">19826393</pub-id></mixed-citation></ref><ref id=\"cit0003\"><label>3.</label><mixed-citation publication-type=\"book\"><string-name name-style=\"western\"><surname>Mackin</surname><given-names>AG</given-names></string-name>, <string-name name-style=\"western\"><surname>Massamba</surname><given-names>N</given-names></string-name>, <string-name name-style=\"western\"><surname>Skondra</surname><given-names>D</given-names></string-name>. <part-title>Panretinal photocoagulation for neovascular glaucoma</part-title>. In: <string-name name-style=\"western\"><surname>Qiu</surname><given-names>M</given-names></string-name> editor. <source><italic toggle=\"yes\">Neovascular Glaucoma</italic></source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2022</year>:<fpage>111</fpage>&#8211;<lpage>119</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1007/978-3-031-11720-6_13</pub-id>.</mixed-citation></ref><ref id=\"cit0004\"><label>4.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Asif</surname><given-names>H</given-names></string-name>, <string-name name-style=\"western\"><surname>Si</surname><given-names>Z</given-names></string-name>, <string-name name-style=\"western\"><surname>Quan</surname><given-names>S</given-names></string-name>, et al. <article-title>Neovascular glaucoma from ocular ischemic syndrome treated with serial monthly intravitreal bevacizumab and panretinal photocoagulation: a case report</article-title>. <source><italic toggle=\"yes\">Case Rep Ophthalmolo Med</italic></source>. <year>2022</year>;<volume>2022</volume>:<fpage>1</fpage>&#8211;<lpage>5</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1155/2022/4959522</pub-id></mixed-citation></ref><ref id=\"cit0005\"><label>5.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style=\"western\"><surname>Chun</surname><given-names>LY</given-names></string-name>, <string-name name-style=\"western\"><surname>Qiu</surname><given-names>M</given-names></string-name>. <article-title>Cyclophotocoagulation in neovascular glaucoma with near-total synechial angle closure</article-title>. <source><italic toggle=\"yes\">Case Rep Ophthalmolo Med</italic></source>. <year>2023</year>;<volume>2023</volume>:<fpage>e5719002</fpage>. doi:<pub-id pub-id-type=\"doi\">10.1155/2023/5719002</pub-id></mixed-citation></ref><ref id=\"cit0006\"><label>6.</label><mixed-citation publication-type=\"book\"><string-name name-style=\"western\"><surname>Shalaby</surname><given-names>WS</given-names></string-name>, <string-name name-style=\"western\"><surname>Amarasekera</surname><given-names>DC</given-names></string-name>, <string-name name-style=\"western\"><surname>Shukla</surname><given-names>AG</given-names></string-name>. <part-title>Aqueous shunt for neovascular glaucoma</part-title>. In: <string-name name-style=\"western\"><surname>Qiu</surname><given-names>M</given-names></string-name> editor. <source><italic toggle=\"yes\">Neovascular Glaucoma</italic></source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2022</year>:<fpage>151</fpage>&#8211;<lpage>166</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1007/978-3-031-11720-6_17</pub-id>.</mixed-citation></ref><ref id=\"cit0007\"><label>7.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Tailor</surname><given-names>R</given-names></string-name>, <string-name name-style=\"western\"><surname>Kinsella</surname><given-names>MT</given-names></string-name>, <string-name name-style=\"western\"><surname>Clarke</surname><given-names>JC</given-names></string-name>. <article-title>Long-term outcome of intravitreal bevacizumab followed by Ahmed valve implantation in the management of neovascular glaucoma</article-title>. <source><italic toggle=\"yes\">Seminars Ophthalmol</italic></source>. <year>2018</year>;<volume>33</volume>(<issue>5</issue>):<fpage>606</fpage>&#8211;<lpage>612</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1080/08820538.2017.1375123</pub-id></mixed-citation></ref><ref id=\"cit0008\"><label>8.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Qiu</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Shukla</surname><given-names>AG</given-names></string-name>, <string-name name-style=\"western\"><surname>Sun</surname><given-names>CQ</given-names></string-name>. <article-title>Improving outcomes in neovascular glaucoma</article-title>. <source><italic toggle=\"yes\">Ophthalmol Glaucoma</italic></source>. <year>2022</year>;<volume>5</volume>(<issue>2</issue>):<fpage>125</fpage>&#8211;<lpage>127</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1016/j.ogla.2021.12.001</pub-id><pub-id pub-id-type=\"pmid\">35031284</pub-id><pub-id pub-id-type=\"pmcid\">PMC10019522</pub-id></mixed-citation></ref><ref id=\"cit0009\"><label>9.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Wakabayashi</surname><given-names>T</given-names></string-name>, <string-name name-style=\"western\"><surname>Oshima</surname><given-names>Y</given-names></string-name>, <string-name name-style=\"western\"><surname>Sakaguchi</surname><given-names>H</given-names></string-name>, et al. <article-title>Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases</article-title>. <source><italic toggle=\"yes\">Ophthalmology</italic></source>. <year>2008</year>;<volume>115</volume>(<issue>9</issue>):<fpage>1571</fpage>&#8211;<lpage>1580.e3</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1016/j.ophtha.2008.02.026</pub-id><pub-id pub-id-type=\"pmid\">18440643</pub-id></mixed-citation></ref><ref id=\"cit0010\"><label>10.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Shakarchi</surname><given-names>FI</given-names></string-name>, <string-name name-style=\"western\"><surname>Shakarchi</surname><given-names>AF</given-names></string-name>, <string-name name-style=\"western\"><surname>Al-Bayati</surname><given-names>SA</given-names></string-name>. <article-title>Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab</article-title>. <source><italic toggle=\"yes\">Clin Ophthalmol</italic></source>. <year>2018</year>;<volume>13</volume>:<fpage>27</fpage>&#8211;<lpage>31</lpage>. doi:<pub-id pub-id-type=\"doi\">10.2147/OPTH.S182420</pub-id><pub-id pub-id-type=\"pmid\">30587917</pub-id><pub-id pub-id-type=\"pmcid\">PMC6304070</pub-id></mixed-citation></ref><ref id=\"cit0011\"><label>11.</label><mixed-citation publication-type=\"book\"><string-name name-style=\"western\"><surname>Viruni</surname><given-names>N</given-names></string-name>, <string-name name-style=\"western\"><surname>Cai</surname><given-names>CX</given-names></string-name>. <part-title>Anti-vascular endothelial growth factor for neovascular glaucoma</part-title>. In: <string-name name-style=\"western\"><surname>Qiu</surname><given-names>M</given-names></string-name> editor. <source><italic toggle=\"yes\">Neovascular Glaucoma</italic></source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2022</year>:<fpage>121</fpage>&#8211;<lpage>130</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1007/978-3-031-11720-6_14</pub-id>.</mixed-citation></ref><ref id=\"cit0012\"><label>12.</label><mixed-citation publication-type=\"book\"><string-name name-style=\"western\"><surname>Salazar</surname><given-names>H</given-names></string-name>, <string-name name-style=\"western\"><surname>Swaminathan</surname><given-names>SS</given-names></string-name>. <part-title>Treatment goals in neovascular glaucoma</part-title>. In: <string-name name-style=\"western\"><surname>Qiu</surname><given-names>M</given-names></string-name> editor. <source><italic toggle=\"yes\">Neovascular Glaucoma</italic></source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2022</year>:<fpage>97</fpage>&#8211;<lpage>109</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1007/978-3-031-11720-6_12</pub-id>.</mixed-citation></ref><ref id=\"cit0013\"><label>13.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Shazly</surname><given-names>TA</given-names></string-name>, <string-name name-style=\"western\"><surname>Latina</surname><given-names>MA</given-names></string-name>. <article-title>Neovascular glaucoma: etiology, diagnosis and prognosis</article-title>. <source><italic toggle=\"yes\">Seminars Ophthalmol</italic></source>. <year>2009</year>;<volume>24</volume>(<issue>2</issue>):<fpage>113</fpage>&#8211;<lpage>121</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1080/08820530902800801</pub-id></mixed-citation></ref><ref id=\"cit0014\"><label>14.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Fontana</surname><given-names>L</given-names></string-name>, <string-name name-style=\"western\"><surname>De Maria</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Iannetta</surname><given-names>D</given-names></string-name>, <string-name name-style=\"western\"><surname>Moramarco</surname><given-names>A</given-names></string-name>. <article-title>Gonioscopy-assisted transluminal trabeculotomy for chronic angle-closure glaucoma: preliminary results</article-title>. <source><italic toggle=\"yes\">Graefes Arch Clin Exp Ophthalmol</italic></source>. <year>2022</year>;<volume>260</volume>(<issue>2</issue>):<fpage>545</fpage>&#8211;<lpage>551</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1007/s00417-021-05400-z</pub-id><pub-id pub-id-type=\"pmid\">34487226</pub-id></mixed-citation></ref><ref id=\"cit0015\"><label>15.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Kanter</surname><given-names>JA</given-names></string-name>, <string-name name-style=\"western\"><surname>Amin</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Komati</surname><given-names>R</given-names></string-name>, et al. <article-title>Gonioscopy-assisted transluminal trabeculotomy in neovascular glaucoma: salvaging the conventional outflow pathway</article-title>. <source><italic toggle=\"yes\">Am J Ophthalmol Case Rep</italic></source>. <year>2022</year>;<volume>28</volume>:<fpage>101668</fpage>. doi:<pub-id pub-id-type=\"doi\">10.1016/j.ajoc.2022.101668</pub-id><pub-id pub-id-type=\"pmid\">36051187</pub-id><pub-id pub-id-type=\"pmcid\">PMC9424943</pub-id></mixed-citation></ref><ref id=\"cit0016\"><label>16.</label><mixed-citation publication-type=\"journal\"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab>. <article-title>Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early treatment diabetic retinopathy study Report No. 3. the early treatment diabetic retinopathy study research group</article-title>. <source><italic toggle=\"yes\">Int Ophthalmol Clin</italic></source>. <year>1987</year>;<volume>27</volume>(<issue>4</issue>):<fpage>254</fpage>&#8211;<lpage>264</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1097/00004397-198702740-00005</pub-id><pub-id pub-id-type=\"pmid\">3692707</pub-id></mixed-citation></ref><ref id=\"cit0017\"><label>17.</label><mixed-citation publication-type=\"journal\"><string-name name-style=\"western\"><surname>Adhi</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Brewer</surname><given-names>E</given-names></string-name>, <string-name name-style=\"western\"><surname>Waheed</surname><given-names>NK</given-names></string-name>, <string-name name-style=\"western\"><surname>Duker</surname><given-names>JS</given-names></string-name>. <article-title>Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography</article-title>. <source><italic toggle=\"yes\">JAMA Ophthalmol</italic></source>. <year>2013</year>;<volume>131</volume>(<issue>10</issue>):<fpage>1267</fpage>&#8211;<lpage>1274</lpage>. doi:<pub-id pub-id-type=\"doi\">10.1001/jamaophthalmol.2013.4321</pub-id><pub-id pub-id-type=\"pmid\">23907153</pub-id><pub-id pub-id-type=\"pmcid\">PMC4045010</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>",
  "text": "pmc Clin Ophthalmol Clin Ophthalmol 909 clinop opth Clinical Ophthalmology (Auckland, N.Z.) 1177-5467 1177-5483 Dove Press PMC12679860 PMC12679860.1 12679860 12679860 41357313 10.2147/OPTH.S557133 557133 1 Original Research SCOPING: A Multidisciplinary Treatment Protocol for Neovascular Glaucoma with Completely Open or Partially Open Angles Mokhashi et al Mokhashi et al http://orcid.org/0000-0001-9510-3747 Mokhashi Nikita 1 Kanter Jacob 2 Komati Rahul 3 Mackin Anna 4 Dao David 5 Amin Pathik 1 Skondra Dimitra 1 http://orcid.org/0000-0002-0062-7386 Qiu Mary 6 1 Department of Ophthalmology and Visual Science, University of Chicago , Chicago , IL , USA 2 Wilmer Eye Institute, Johns Hopkins University , Baltimore , MD , USA 3 Georgia Retina , Macon , GA , USA 4 Vistar Eye Center , Roanoke , VA , USA 5 Elman Retina Group , Rosedale , MD , USA 6 Cole Eye Institute, Cleveland Clinic , Cleveland , OH , USA Correspondence: Mary Qiu, Cole Eye Institute, Cleveland Clinic , 2022 E 105 th St , Cleveland , OH , 44106 , USA , Email mary.qiu@gmail.com 01 12 2025 2025 19 478874 4373 4379 30 7 2025 11 11 2025 01 12 2025 06 12 2025 08 12 2025 &#169; 2025 Mokhashi et al. 2025 Mokhashi et al. https://creativecommons.org/licenses/by-nc/4.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v4.0) License ( http://creativecommons.org/licenses/by-nc/4.0/ ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php ). Introduction A standardized multidisciplinary treatment protocol for NVG was developed in 2020 at the University of Chicago and has been termed Salvaging the Conventional Outflow Pathway in Neovascular Glaucoma (SCOPING). We describe 9 eyes with anterior segment neovascularization and at least partially open angles that underwent the SCOPING protocol to suppress the underlying neovascular drive, control intraocular pressure, and medically or surgically salvage the angle whenever possible. Methods Nine eyes from 8 patients with first-time anterior segment neovascularization, at least partially open angles, and normal or elevated IOP were treated with 6 serial monthly intravitreal bevacizumab injections interspersed with pan-retinal photocoagulation. Results Five eyes with completely open angles without any peripheral anterior synechiae and each achieved and/or maintained physiologic IOP without requiring surgery. The other 4 eyes presented with partially open angles. Three out of these 4 eyes required subsequent IOP-lowering surgery. None of the 9 eyes developed recurrence of anterior segment neovascularization during the treatment protocol. Discussion This protocol may be utilized to salvage the conventional outflow pathway for patients with partially or completely open angles. The etiology and diagnosis of neovascular glaucoma have been established. Current treatment strategies include reduction of neovascular drive including panretinal photocoagulation, intravitreal injections, intraocular pressure lowering medications, and filtration surgery. However, a protocol has not been developed to treat neovascular glaucoma (NVG). Our SCOPING protocol may be helpful for glaucoma specialists in treating patients with neovascular glaucoma. Keywords neovascular glaucoma micro invasive glaucoma surgeries anti-vascular endothelial growth factor pan-retinal photocoagulation funding or grant support No funding or grant support was used. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes Introduction Neovascular glaucoma (NVG) is a secondary glaucoma that occurs when retinal ischemia leads to the proliferation of fibrovascular tissue anteriorly, leading to neovascularization of the iris (NVI) and/or angle (NVA) with a subsequent increase in intraocular pressure (IOP). 1 The management of NVG centers around reducing the vascular endothelial growth factor (VEGF) load and controlling IOP. The two approaches to reduce the VEGF load are intravitreal anti-VEGF therapy such as bevacizumab (IVB) and panretinal photocoagulation (PRP). IVB leads to rapid regression of NVA and NVI which can also contribute to IOP-lowering if the angle is at least partially open and functional. 2 While anti-VEGF works immediately, PRP is the gold standard long term solution as it decreases the underlying neovascular drive by inducing tissue coagulation thereby decreasing the production of angiogenic factors by peripheral ischemic retina. 3 If the patient presents with NVI or NVA without synechial closure, regression of the anterior neovascularization through anti-VEGF and PRP may be sufficient to achieve physiologic IOP without the need for any glaucoma intervention. 4 However, eyes with NVG that have already developed partial or total synechial angle closure often require interventions such as tube shunt implantation or cyclophotocoagulation (CPC) to achieve long-term IOP control. 5 , 6 As a whole, long-term NVG outcomes leave much to be desired, 7 and there are many barriers to achieving optimal outcomes in NVG. 8 For this reason, a standardized multidisciplinary treatment protocol for NVG was developed in 2020 in collaboration between a glaucoma (MQ) and retina (DS) specialist at the University of Chicago and has been termed Salvaging the Conventional Outflow Pathway in Neovascular Glaucoma (SCOPING). For eyes with anterior segment neovascularization (NVI or NVA) and at least partially open angles, regardless of presenting IOP or presumed visual potential (as long as not already NLP at presentation), we offer an aggressive anti-neovascular treatment protocol in an attempt to medically salvage the conventional outflow pathway and reduce the need for subsequent IOP-lowering surgeries. If IOP becomes uncontrolled on maximum medical therapy, angle-based surgeries may be offered to qualifying patients with the goal of salvaging the conventional outflow pathway whenever possible and delaying or potentially avoiding a tube shunt or CPC. Materials and Methods Approval was obtained from the University of Chicago Institutional Review Board (IRB) to perform a retrospective chart review to describe treatment outcomes. Patient consent to review medical records was not required per the University of Chicago IRB given the deidentified nature of the data collected. This work adhered to the 1964 Helsinki declaration and its later amendments. Patients with first-time anterior segment neovascularization (NVI or NVA) and at least partially open angles (defined as no more than 270&#176; of synechial closure) and normal or elevated IOP 9 were treated with 6 planned serial monthly IVB injections interspersed with sessions of PRP at the discretion of the retina service with the goal of providing anti-neovascular coverage with the planned monthly injections while sufficient PRP is administered. Given the practice patterns of the retina service, we collaboratively decided to standardize the treatment protocol to 6 scheduled monthly injections, to provide up to 6 months of time for the PRP to be completed. However, depending on the retina specialists&#8217; practice pattern, patients may require greater or fewer than 6 monthly injections to provide an adequate umbrella of anti-neovascular protection while sufficient PRP is completed. Qualifying patients were stratified into 3 stages of disease: patients with NVI or NVA, normal IOP, and absence of PAS; patients with NVI or NVA, elevated IOP, and absence of PAS; and patients with NVI or NVA, elevated IOP, and presence of PAS with partial synechial closure (&lt;75% closure). IVB injections were encouraged to be spaced by 28 days to maintain continuous anti-neovascular protection while the eye undergoes multiple sessions of PRP which has a slower onset of action. 3 , 10 , 11 If the IOP became elevated despite maximum medical IOP-lowering therapy, and there was no active anterior segment neovascularization, then angle surgery such as gonioscopy assisted transluminal trabeculotomy (GATT) was offered in an attempt to surgically salvage the conventional outflow pathway. Contraindications for GATT included monocular status and inability to hold antiplatelet/anticoagulation. Patients who were considered candidates for GATT first could alternatively elect primary aqueous shunt or CPC instead, depending on the clinical circumstances. Herein, we report pilot results from 9 consecutive NVG eyes that completed the SCOPING protocol, defined as completing 6 scheduled monthly anti-VEGF injections, with as many interspersed PRP sessions as was deemed necessary by the retina service. Results In total, 9 eyes from 8 patients qualified for and completed the SCOPING protocol. Presenting clinical characteristics and outcomes are shown in Table 1 . Humphrey visual field and OCT testing can be confounded in the setting of NVG due to corneal and retinal findings leading to misinterpretation, thus they were not necessarily performed at baseline in these NVG patients. 12 , 13 The 2 eyes with anterior segment neovascularization and normal IOP were diagnosed despite being asymptomatic because their fellow eye presented symptomatically with NVG and total synechial angle closure. Table 1 Demographic Characteristics and Clinical Features of Eyes Presenting with NVI/NVA and Completely or Partially Open Angles Undergoing SCOPING Protocol Eye Age at Presentation Gender (M/F) Race Etiology PRP Prior to Presentation of NVG Aspirin/AC Use Initial VA Initial IOP (mmHg) Iris/Angle Exam Duration Between 6 IVBs (Days) # PRP Session (# of Spots) Within Protocol Period VA 1 Month After IVB #6 IOP 1 Month After IVB #6 Recurrent NV During Study Period? Recurrent NV After Study Period? IOP-Lowering Surgery at Any Point Subsequent Anti-VEGF Therapy After Protocol Period # Days Since Protocol Completion to Last Visit VA at Last Visit IOP at Last Visit Anterior Segment Neovascularization with Normal IOP Eye #1 60s F Black PDR Yes AC 20/25 14 on 0 meds NVI , no NVA, no PAS 33, 37, 48, 43, 42 3 (1677) 20/20 9 on 0 meds No No None Subsequent IVB &amp; PRP&#8224; and aflibercept 980 20/40 14 on 0 meds Eye #2* 60s M Black PDR Yes AC 20/50 15 on 0 meds NVI , no NVA, no PAS 28, 30, 77, 33, 28 1 (642) 20/30 19 on 0 meds No No None Subsequent IVB 539 20/30 18 on 0 meds Anterior Segment Neovascularization with Elevated IOP and an Open Angle without PAS Eye #3* 60s M Hispanic PDR Yes ASA 20/30 38 on 0 meds NVI, faint NVA , no PAS 28, 69, 42, 42, 28 3 (1878) 20/25 12 on 2 meds No No None None at 56 days 44 20/25 12 on 2 meds Eye #4* 60s M Hispanic PDR Yes ASA 20/40 41 on 0 meds NVI, faint NVA , no PAS 28, 63, 42, 42, 28 2 (1303) 20/30 10 on 2 meds No No None Subsequent PRP 51 20/30 10 on 2 meds Eye #5 60s M Caucasian OIS No None 20/50 47 on 0 meds NVI, faint NVA , no PAS 28, 35, 28, 28, 33 3 (1907) 20/20 19 on 0 meds No Yes&#8225; None Subsequent IVB &amp; PRP 920 20/20 19 on 0 meds Anterior Segment Neovascularization with Elevated IOP and Partial Synechial Closure (&lt;75% closure) Eye #6 20s M Black PDR No None 20/40 22 on 0 meds NVI, frank NVA, 30% PAS 29, 28, 28, 28, 28 3 (3268) 20/40 20 on 0 meds No Yes** No Subsequent IVB &amp; PRP 459 20/40 17 on 2 meds Eye #7 40s M Hispanic PDR No None 20/100 31 on 4 meds Regressed NVI, no NVA, 50% PAS 28, 38, 29, 23, 40 1 (&#167;&#167;) 20/50 13 on 3 meds No Yes GATT &amp; IVTA&#8224;&#8224; between IVB #1 and #2; subsequent BGI 350 Subsequent IVB &amp; PRP 241 20/400 18 on 1 med Eye #8* 50s F Black CRVO No None HM 45 on 0 meds NVI, frank NVA, 50% PAS 35, 61, 51, 33, 44 2 (2386) 20/200 15 on 2 meds No Yes*** GATT between IVB #2 and #3; subsequent CPC &amp; BGI 350 Subsequent IVB &amp; PRP 439 20/125 8 on 0 meds Eye #9 50s F Black PDR No ASA 20/40 31 on 0 meds NVI, frank NVA, 50% PAS 34, 23, 40, 72, 35 2 (1933) 20/30 18 on 0 meds No No BGI 350 between IVB #1 and #2 Subsequent IVB &amp; PRP&#167; 776 20/30 11 on 4 meds Notes : *Four eyes from 3 patients who died after completion of the protocol; &#8224;Starting 152 days after IVB #6 for vitreous hemorrhage; &#167;&#167; # of PRP spots not documented in electronic medical record. &#8224;&#8224;80 days after IVB #6 for recurrent NVA; **158 days after IVB #6; &#8224;&#8224;intravitreal triamcinolone acetonide; ***119 days after IVB #6 for recurrent NVA; &#167;Further IVB in order to dry out CME prior to performing fill-in PRP. Abbreviations : AC, anticoagulation; BGI350, Baerveldt 350; CPC, Cyclophotocoagulation; CRVO, Central retinal vein occlusion; F, female; GATT, Gonioscopy-assisted transluminal trabeculotomy; HM, Hand motion; IOP, Intraocular pressure; IVB, Intravitreal bevacizumab; M, male; NVA, Neovascularization of the angle; NV, Neovascularization; NVG, Neovascular Glaucoma; NVI, Neovascularization of the iris; OIS, Ocular ischemic syndrome; PAS, Peripheral anterior synechiae; PDR, Proliferative diabetic retinopathy; PRP, Panretinal photocoagulation; VA, Visual acuity; VEGF, Vascular endothelial growth factor. There were 5 male patients, and 5 patients were African American. The median age was 60.5 years (range 25&#8211;68). The median presenting VA was 20/40 and the mean presenting IOP was 31&#160;mmHg on 0 medications. IVB was given within 1 day of diagnosis for all but 1 patient who received an injection at a referring doctor&#8217;s office 7 days prior to urgent follow up with University of Chicago. Median duration between subsequent IVBs was 35 days (range 23 to 77), median time from IVB #1 to IVB #6 was 203 days (range 152 to 224), and median number of PRP sessions during the protocol period was 2 (range 1&#8211;3). One month after IVB #6, median IOP was 15&#160;mmHg (range 9&#8211;20) on a median of 2 medications (range 0&#8211;2). Five eyes presented with anterior segment neovascularization and a completely open angle without any peripheral anterior synechiae (PAS). Among these, 2 eyes had normal IOP and NVA while 3 eyes had elevated IOP and NVA. These 5 eyes all achieved and/or maintained physiologic IOP without IOP-lowering surgery to date. Notably, 3 of the 5 eyes underwent subsequent IVB beyond the 6-month SCOPING protocol period: one for cystoid macular edema secondary to PDR, one for vitreous hemorrhage secondary to PDR, and one for recurrent NVA and elevated IOP in the setting of ocular ischemic syndrome. 4 These 3 angles remained completely open with the resumption of serial anti-VEGF therapy. Among the 4 eyes (eyes #6-9) with partial angle closure at the time of presentation, 1 eye (eye #6) was still partially open after completion of the SCOPING protocol and has not required any further procedures. The other 3 eyes (eye #7-9) underwent further procedures. Eye #7 underwent a GATT between IVB #1 and #2 for elevated IOP on 4 medications. Although GATT is typically contraindicated in eyes with PAS, it can be completed 14 and was successfully performed in eye #8 with NVG and PAS. 15 After GATT, eye #7 received anti-VEGF injections with a local retina specialist but there was a lapse in retina follow-up, and this eye did not receive anti-VEGF injections for 82 days. Due to this lapse, this eye subsequently developed recurrent NVI and NVA with total synechial angle closure and elevated IOP and underwent a Baerveldt-350 in the sulcus 5 months after SCOPING protocol completion. This was likely due to incomplete PRP as this patient had only 1 session. Similarly, eye #8 also underwent GATT 35 days after NVG presentation. Eye #8 subsequently achieved medication-free IOP control for 9 months while undergoing monthly anti-VEGF injections before subsequently becoming lost to follow-up. This eye developed recurrent disease with subsequent total synechial angle closure, requiring Baerveldt-350 in the sulcus 9 months after completing the SCOPING protocol. 15 In eyes #7 and #8 with progressive synechial closure, the anti-VEGF had ample time to take effect in regressing anterior segment neovascularization since the angle was partially open on presentation, so GATT could be performed after regression. Eye #9, despite initially being an anatomic candidate for GATT, underwent Baerveldt-350 in the sulcus 8 days after NVG presentation as the patient elected for an aqueous shunt instead. Discussion Our results demonstrate the value of prompt and aggressive anti-VEGF treatment for anterior segment neovascularization with completely open or partially open angles. IVB leads to immediate regression of NVI and NVA which is maintained while serial injections keep neovascularization at bay. Under the coverage of monthly IVB, interspersed sessions of PRP exert a long-lasting effect beyond the completion of injections. Once sufficient PRP has been completed, serial monthly injections can be stopped. However, it is important to realize that sufficient PRP is difficult to define. The Early Treatment Diabetic Retinopathy Study (ETDRS) defined sufficient PRP as 1200 to 1600 burns which should extend to the edge of an oval area including the disc and macula, and anteriorly to or beyond the equator. 16 Of the eyes that had recurrence after completion of the study protocol (eyes #5-8), eye #7 only had 1 session of PRP which was insufficient according to this definition. The other 3 eyes (eyes #5, #6 and #8) did have greater than 1600 burns documented. It is possible that these 3 eyes also did not have sufficient PRP but it is also possible that despite maximal PRP, they had persistent neovascularization from uveal ischemia which would not be addressed by PRP. 16 Indeed, there are some choroidal vascular changes that have been documented in PDR and DME, including decreased combined thickness of the choriocapillaris and medium choroidal vessel layers. 17 Once PRP is completed, one could consider obtaining a fluorescein angiogram to assess for areas of persistent leakage, or OCT angiography to assess for choroidal ischemia. With prompt control of neovascular drive, there may be a window of opportunity to salvage the angle medically or surgically, if necessary. Our results reflect the importance of stratifying eyes with anterior segment neovascularization by angle status as described above. For eyes that present with anterior segment neovascularization with a completely open angle, this protocol may allow them to maintain or achieve physiologic IOP without any subsequent IOP-lowering surgery. For eyes that present with partial synechial angle closure, this protocol allows rapid regression of anterior segment neovascularization and temporary improvement of IOP so that any subsequent IOP-lowering surgery can be considered only after anterior segment neovascularization has fully regressed. Microinvasive glaucoma surgeries such as GATT may be attempted to surgically salvage and/or restore the conventional outflow pathway in select eyes if the patient and team are committed to close follow-up and ongoing treatment. Of the 4 patients who had NVI/NVA with elevated IOP and PAS with partial synechial closure, 3 required IOP-lowering surgery as described above. The patient who elected to have primary BGI 350 did not have recurrence of neovascularization (eye #9). However, the other 2 patients (eyes #7 and #8) who elected to try GATT first may have had insufficient PRP during the 6-month window of anti-VEGF to completely regress their neovascular drive. Thus, while their IOP was controlled during their monthly anti-VEGF in the protocol period, they developed recurrent NVA with subsequent progressive synechial angle closure requiring additional IOP-lowering surgery with BGI-350 in the sulcus. These 2 patients demonstrate that the angle can be salvaged as long as the neovascular drive is controlled. Crucially, sufficient PRP must be completed while patients are receiving short-term coverage with anti-VEGF in order to allow long term control once the injections are stopped. If they do not get full PRP within this period of coverage, neovascularization may recur if there is a break in regular injections. Each of the patients in this pilot study had at least a partially open angle. In NVG eyes with total synechial closure (defined as more than 270&#176; of synechial closure) and active anterior segment neovascularization, prompt cyclophotocoagulation with anti-VEGF was recommended as the primary intervention, and we have published our outcomes for those patients separately. 5 In such patients, IOP would not be expected to improve with regression of anterior segment neovascularization as the angle is already synechially closed. 9 Our study has limitations. First it is a retrospective pilot study with small sample size. Additionally, as it is based on 9 individual patients, there is variability in compliance with treatment and follow up. However, we offer a novel and unique protocol to treat neovascular glaucoma which is valuable given the limited guidelines currently available. Conclusion The SCOPING protocol may be utilized to salvage the conventional outflow pathway for patients with any anterior segment neovascularization regardless of IOP when the angle is completely or partially open. Further directions include comparison of outcomes in patients with neovascular glaucoma treated prior to the development of the SCOPING protocol. Acknowledgments The abstract of this paper was presented at the Women in Ophthalmology Conference in 2023 as a poster presentation with interim findings. Data Sharing Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. Patient Consent Consent to publish personal information and case details was obtained verbally from the patients included in this report. No individual patients are identifiable by their case description. Disclosure Mary Qiu reports personal fees from Lantrek, personal fees from New World Medical, personal fees from Abbvie, personal fees from Nova, outside the submitted work. The authors report no other conflicts of interest in this work. References 1. Khanna S , Chang DS . Epidemiology of neovascular glaucoma . In: Qiu M editor. Neovascular Glaucoma . Springer International Publishing ; 2022 : 5 &#8211; 9 . doi: 10.1007/978-3-031-11720-6_2 . 2. Yazdani S , Hendi K , Pakravan M , Mahdavi M , Yaseri M . Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial . J Glaucoma . 2009 ; 18 ( 8 ): 632 &#8211; 637 . doi: 10.1097/IJG.0b013e3181997211 19826393 3. Mackin AG , Massamba N , Skondra D . Panretinal photocoagulation for neovascular glaucoma . In: Qiu M editor. Neovascular Glaucoma . Springer International Publishing ; 2022 : 111 &#8211; 119 . doi: 10.1007/978-3-031-11720-6_13 . 4. Asif H , Si Z , Quan S , et al. Neovascular glaucoma from ocular ischemic syndrome treated with serial monthly intravitreal bevacizumab and panretinal photocoagulation: a case report . Case Rep Ophthalmolo Med . 2022 ; 2022 : 1 &#8211; 5 . doi: 10.1155/2022/4959522 5. Wang J , Chun LY , Qiu M . Cyclophotocoagulation in neovascular glaucoma with near-total synechial angle closure . Case Rep Ophthalmolo Med . 2023 ; 2023 : e5719002 . doi: 10.1155/2023/5719002 6. Shalaby WS , Amarasekera DC , Shukla AG . Aqueous shunt for neovascular glaucoma . In: Qiu M editor. Neovascular Glaucoma . Springer International Publishing ; 2022 : 151 &#8211; 166 . doi: 10.1007/978-3-031-11720-6_17 . 7. Tailor R , Kinsella MT , Clarke JC . Long-term outcome of intravitreal bevacizumab followed by Ahmed valve implantation in the management of neovascular glaucoma . Seminars Ophthalmol . 2018 ; 33 ( 5 ): 606 &#8211; 612 . doi: 10.1080/08820538.2017.1375123 8. Qiu M , Shukla AG , Sun CQ . Improving outcomes in neovascular glaucoma . Ophthalmol Glaucoma . 2022 ; 5 ( 2 ): 125 &#8211; 127 . doi: 10.1016/j.ogla.2021.12.001 35031284 PMC10019522 9. Wakabayashi T , Oshima Y , Sakaguchi H , et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases . Ophthalmology . 2008 ; 115 ( 9 ): 1571 &#8211; 1580.e3 . doi: 10.1016/j.ophtha.2008.02.026 18440643 10. Shakarchi FI , Shakarchi AF , Al-Bayati SA . Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab . Clin Ophthalmol . 2018 ; 13 : 27 &#8211; 31 . doi: 10.2147/OPTH.S182420 30587917 PMC6304070 11. Viruni N , Cai CX . Anti-vascular endothelial growth factor for neovascular glaucoma . In: Qiu M editor. Neovascular Glaucoma . Springer International Publishing ; 2022 : 121 &#8211; 130 . doi: 10.1007/978-3-031-11720-6_14 . 12. Salazar H , Swaminathan SS . Treatment goals in neovascular glaucoma . In: Qiu M editor. Neovascular Glaucoma . Springer International Publishing ; 2022 : 97 &#8211; 109 . doi: 10.1007/978-3-031-11720-6_12 . 13. Shazly TA , Latina MA . Neovascular glaucoma: etiology, diagnosis and prognosis . Seminars Ophthalmol . 2009 ; 24 ( 2 ): 113 &#8211; 121 . doi: 10.1080/08820530902800801 14. Fontana L , De Maria M , Iannetta D , Moramarco A . Gonioscopy-assisted transluminal trabeculotomy for chronic angle-closure glaucoma: preliminary results . Graefes Arch Clin Exp Ophthalmol . 2022 ; 260 ( 2 ): 545 &#8211; 551 . doi: 10.1007/s00417-021-05400-z 34487226 15. Kanter JA , Amin P , Komati R , et al. Gonioscopy-assisted transluminal trabeculotomy in neovascular glaucoma: salvaging the conventional outflow pathway . Am J Ophthalmol Case Rep . 2022 ; 28 : 101668 . doi: 10.1016/j.ajoc.2022.101668 36051187 PMC9424943 16. Early Treatment Diabetic Retinopathy Study Research Group . Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early treatment diabetic retinopathy study Report No. 3. the early treatment diabetic retinopathy study research group . Int Ophthalmol Clin . 1987 ; 27 ( 4 ): 254 &#8211; 264 . doi: 10.1097/00004397-198702740-00005 3692707 17. Adhi M , Brewer E , Waheed NK , Duker JS . Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography . JAMA Ophthalmol . 2013 ; 131 ( 10 ): 1267 &#8211; 1274 . doi: 10.1001/jamaophthalmol.2013.4321 23907153 PMC4045010"
}